AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$BLCO

Bausch & Lomb Corp (BLCO) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth

Bausch & Lomb Corp (BLCO) reported Q3 2026 revenue growth of 8%, with all segments showing gains. Adjusted EBITDA rose 34% to $325M. The company raised full-year revenue and EBITDA guidance. Key products like MIBO and Lumify saw strong growth, while surgical equipment revenue declined 11%. The company faces regulatory and competitive pressures. Leadership changes were announced, with Tom Appio becoming interim CEO.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bausch & Lomb Corp (BLCO) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BLCOBullishHigh
01

Why it matters

The earnings beat and guidance raise provide fresh data for traders to adjust positions.

02

Market read

The earnings release is a primary catalyst for BLCO and may influence related healthcare stocks.

03

What to watch

Potential regulatory risks for pipeline projects and foreign exchange headwinds could temper upside.

Relevance 8/10Novelty 8/10Timing: post-market release

Background

Bausch & Lomb reported its Q3 2026 results, highlighting growth across all segments and raising its FY guidance.

Company-level read

Ticker impact

$BLCOBullishHigh confidence
Context

Q3 2026 earnings call disclosed 8% revenue growth, 34% EBITDA increase and raised full-year guidance.

Expected impact

likely upside as market prices in higher revenue and EBITDA guidance

Evidence & confidence

Revenue and EBITDA beat expectations; guidance raised for the third time this year, indicating robust operating performance.

Market effects

Sector

Positive earnings may lift the broader ophthalmic and medical device sector.

Regional

U.S. healthcare stocks could see modest gains.

Global

Limited to investors tracking U.S. med‑tech equities.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, any miss on Q4 could trigger a pullback.

Key entities

  • company
    Bausch & Lomb Corp

    U.S.-listed ophthalmic and medical device company (NYSE:BLCO).

  • executive
    Tom Appio

    Interim CEO who discussed operational focus and potential M&A.

Read at source← All news

StoryBausch + Lomb posts strong Q3 2026 results and lifts full‑year revenue and EBITDA guidance

Also covered by

6 outlets

Related articles

OCT 29
$BLCOMedAI 8/10

What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call

Bausch + Lomb (BLCO) reported Q3 earnings, highlighting growth across multiple franchises. Adjusted gross margin rose to 64.7%, with operating cash flow at $233M. The company raised its 2026 revenue outlook to $5.45B-$5.55B and adjusted EBITDA guidance to $1.09B-$1.14B. Interim CEO Appio focused on profitability and R&D pipeline advancements.

finance.yahoo.com3 min
OCT 28
$BLCOHighAI 8/10

Bausch + Lomb Soars 16% on Big Q3 Profit Beat and Raised Full-Year Guidance

Bausch + Lomb's shares rose 16% after Q3 earnings beat expectations, with adjusted EPS at $0.34 vs. $0.22 consensus and revenue up 7% to $1.375B. Adjusted EBITDA increased 34% to $325M, and the company raised its full-year EBITDA guidance by $65M. Key growth drivers included MIEBO, LUMIFY, and premium intraocular lenses. Johnson & Johnson's contact lens sales also grew, contrasting with Cooper Companies' flat sales.

finance.yahoo.com2 min
OCT 28
$BLCOMed

Bausch + Lomb: Q3 Earnings Snapshot

Bausch + Lomb (BLCO) reported Q3 net income of $32M, or 9 cents per share, beating estimates. Adjusted EPS was 34 cents. Revenue was $1.38B, also topping forecasts. The company expects full-year revenue of $5.45B-$5.55B. Shares are up 14% YTD and 26% over 12 months.

finance.yahoo.com1 min
OCT 28
$BLCOHighAI 9/10

Bausch + Lomb (BLCO) stock trades up, here is why

Bausch + Lomb (BLCO) shares rose 8.7% after reporting Q3 2026 revenue of $1.375B, up 7% YoY, and raising full-year revenue guidance to $5.5B. Adjusted EPS and EBITDA exceeded estimates, reaching 34 cents and $325M, respectively. The company's stock has gained 16.8% YTD, hitting a 52-week high of $19.37.

financialcontent.com2 min